Patient Assistance Programs
Support Programs Overview 

The Reimbursement Connection® provides personalized support regarding reimbursement policies, coding and billing procedures, prior authorization and claims appeals for Amgen products such as Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), and NEUPOGEN® (Filgrastim). One call helps you resolve issues and obtain reimbursement results.

How can the Reimbursement Connection® help you?
  • Review coverage requirements for Aranesp® and Neulasta®
  • Provide coding and billing assistance
  • Explain payor reimbursement policies
  • Provide prior authorization support
  • Provide information regarding claims appeal procedures
  • Help identify alternative sources of payment
  • Provide information regarding the Amgen SAFETY NET® Program for medically needy patients

When calling the Reimbursement Connection®, please be prepared with the following information:

  • Written patient's authorization to disclose patient-identifiable and medical information (required)
  • Name and address of the physician
  • Date of service
  • Patient's name and ID number
  • Name and address of insurer
  • Insurer's reason for rejecting the claim (if applicable)
  • Copy of the claim or explanation of benefits (EOB) (if applicable)

Download Patient Authorization Form (PDF, 45 Kb)

You need to have Adobe® Acrobat® installed to view PDF files. If you do not have Acrobat® Reader®, you can download it for free from Adobe® website.

Adobe® Reader® is a registered trademark of Adobe Systems, Inc. The information provided in this section is of a general nature and for informational purposes only. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters and appropriate coding for a particular patient and/or procedure is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

 

Neulasta® Indication and Important Product Safety Information

Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Product Safety Information

Splenic rupture (including fatal cases), acute respiratory distress syndrome, and sickle cell crises have been reported. Allergic reactions, including anaphylaxis, have also been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment.
In a placebo-controlled trial, bone pain occurred at a higher incidence in Neulasta®-treated patients as compared to placebo-treated patients (31% vs 26%). The most common adverse events reported in either placebo- or active-controlled trials were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain.

© 2007 Amgen All Rights Reserved. Prescribing Information for Neulasta®